Neuronal protection in stroke by an sLex-glycosylated complement inhibitory protein.
暂无分享,去创建一个
Yuan Zhang | Yuan Zhang | E. Connolly | D. Pinsky | R. Mealey | A. Tenner | H. Marsh | H. Marsh | J. Huang | Y. Zhang | L. J. Kim | Richard A. Mealey | Judy Huang
[1] E. Connolly,et al. CD18-mediated neutrophil recruitment contributes to the pathogenesis of reperfused but not nonreperfused stroke. , 1999, Stroke.
[2] A. C. Sen,et al. Recombinant Glycoproteins That Inhibit Complement Activation and Also Bind the Selectin Adhesion Molecules* , 1999, The Journal of Biological Chemistry.
[3] M. Wilson,et al. Complement inhibition prevents gut ischemia and endothelial cell dysfunction after hemorrhage/resuscitation. , 1998, Surgery.
[4] J. Grotta,et al. Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice. , 1998, Stroke.
[5] M. Oz,et al. Complement activation as a cause for primary graft failure in an isogeneic rat model of hypothermic lung preservation and transplantation. , 1997, Transplantation.
[6] J. Sixma,et al. Soluble adhesion molecules reflect endothelial cell activation in ischemic stroke and in carotid atherosclerosis. , 1997, Stroke.
[7] E. Connolly,et al. Use of a spectrophotometric hemoglobin assay to objectively quantify intracerebral hemorrhage in mice. , 1997, Stroke.
[8] L. Klickstein,et al. Complement receptor type 1 (CR1, CD35) is a receptor for C1q. , 1997, Immunity.
[9] L. Koenderman,et al. Platelet-dependent primary hemostasis promotes selectin- and integrin-mediated neutrophil adhesion to damaged endothelium under flow conditions. , 1996, Blood.
[10] Brian J Cummings,et al. Localization and Cell Association of C1q in Alzheimer's Disease Brain , 1996, Experimental Neurology.
[11] B. Furie,et al. The Molecular Basis of Platelet and Endothelial Cell Interaction with Neutrophils and Monocytes: Role of P-Selectin and the P-Selectin Ligand, PSGL-1 , 1995, Thrombosis and Haemostasis.
[12] N. Jamieson,et al. Regulation of the complement cascade by soluble complement receptor type 1. Protective effect in experimental liver ischemia and reperfusion. , 1995, Transplantation.
[13] V. Vetvicka,et al. Microvascular effects of complement blockade with soluble recombinant CR1 on ischemia/reperfusion injury of skeletal muscle. , 1993, Journal of immunology.
[14] W. Baumgartner,et al. Complement inhibition with soluble complement receptor type 1 in cardiopulmonary bypass. , 1993, The Annals of thoracic surgery.
[15] G. R. Carson,et al. Cell surface expression of the C3b/C4b receptor (CR1) protects Chinese hamster ovary cells from lysis by human complement. , 1992, The Journal of biological chemistry.
[16] Steven A. Johnson,et al. Complement mRNA in the mammalian brain: Responses to Alzheimer's disease and experimental brain lesioning , 1992, Neurobiology of Aging.
[17] T. Lindsay,et al. Soluble complement receptor type 1 ameliorates the local and remote organ injury after intestinal ischemia-reperfusion in the rat. , 1992, Journal of immunology.
[18] K. Reid,et al. Gene expression of the A- and B-chain of mouse C1q in different tissues and the characterization of the recombinant A-chain. , 1991, Journal of immunology.
[19] G. R. Carson,et al. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. , 1990, Science.
[20] R A Swanson,et al. A Semiautomated Method for Measuring Brain Infarct Volume , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[21] N. Cooper,et al. Purification and radiolabeling of human C1q. , 1981, Journal of immunology.